Table 3.
Number of animals with data for study procedures
| Control | 10 Gy | 20 Gy | |
|---|---|---|---|
| n | 12 | 11 | 12 |
| Surviving to study end | 12 | 10 | 10 |
| TMET | 10 | 10 | 10 |
| End-study echo | 12 | 10 | 10 |
| Cath ESPVR | 7 | 8 | 7 |
| Cath EDPVR | 7 | 9 | 7 |
| Cath LVEDP | 10 | 10 | 7 |
| Cath CVP | 9 | 10 | 7 |
| Cath MCFP | 11 | 10 | 8 |
| MVD | 12 | 10 | 10 |
| Fibrosis | 12 | 10 | 10 |
| Cardiomyocyte size | 10 | 10 | 9 |
| DHE | 5 | 6 | 5 |
| MnSOD | 10 | 10 | 7 |
| Smad | 8 | 9 | 8 |
| cGMP | 8 | 10 | 8 |
| In vitro PKG activity | 8 | 8 | 8 |
| PKG protein dimer/monomer | 9 | 5 | 5 |
| VASP | 8 | 10 | 8 |
n, Number of animals. TMET, treadmill exercise test; echo, echocardiography; Cath, cardiac catheterization; ESPVR, end-systolic pressure-volume relationship; EDPVR, end-diastolic pressure-volume relationship; LVEDP, left ventricular end-diastolic pressure; CVP, central venous pressure; MCFP, mean circulatory filling pressure; MVD, microvascular density; DHE, dihydroethidium.